Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term 80 and over Aged. Found 176 abstracts

no pagination
Koutrouli N, Anagnostopoulos F, Tsikkinis A, Papastylianou D, Lepore S. Psychometric properties of the Greek version of the Social Constraints Scale in a sample of women with breast cancer. Women Health. 2016 Jan;56(4):413-27.
Li D, Moughan J, Crane C, Hoffman JP, Regine WF, Abrams RA, Safran H, Liu C, Chang P, Freedman GM, Winter KA, Guha C, Abbruzzese JL. RECQ1 A159C Polymorphism Is Associated With Overall Survival of Patients With Resected Pancreatic Cancer: A Replication Study in NRG Oncology Radiation Therapy Oncology Group 9704. Int J Radiat Oncol Biol Phys. 2016 Mar;94(3):554-60.   PMCID: PMC4876948
Shah JJ, Jakubowiak AJ, O'Connor OA, Orlowski RZ, Harvey RD, Smith MR, Lebovic D, Diefenbach C, Kelly K, Hua Z, Berger AJ, Mulligan G, Faessel HM, Tirrell S, Dezube BJ, Lonial S. Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma. Clin Cancer Res. 2016 Nov 11;22(1):34-43.
Wang HH, Zaorsky NG, Meng MB, Zeng XL, Deng L, Song YC, Zhuang HQ, Li FT, Zhao LJ, Yuan ZY, Wang P, Hao XS. Stereotactic radiation therapy for oligometastases or oligorecurrence within mediastinal lymph nodes. Oncotarget. 2016 Apr 05;7(14):18135-45.   PMCID: PMC4951277
Wang HH, Zaorsky NG, Meng MB, Zeng XL, Deng L, Song YC, Zhuang HQ, Li FT, Zhao LJ, Yuan ZY, Wang P, Hao XS. Stereotactic radiation therapy for oligometastases or oligorecurrence within mediastinal lymph nodes. Oncotarget. 2016 Apr 05;7(14):18135-45.   PMCID: PMC4951277
Balamucki CJ, DeJesus R, Galloway TJ, Mancuso AA, Amdur RJ, Morris CG, Kirwan JM, Mendenhall WM. Impact of radiographic findings on for prognosis skin cancer with perineural invasion. Am J Clin Oncol. 2015 Jun;38(3):248-51.
Coleman RL, Sill MW, Bell-McGuinn K, Aghajanian C, Gray HJ, Tewari KS, Rubin SC, Rutherford TJ, Chan JK, Chen A, Swisher EM. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2015 Jun;137(3):386-91.   PMCID: 4447525
Dabaja BS, Vanderplas AM, Crosby-Thompson AL, Abel GA, Czuczman MS, Friedberg JW, Gordon LI, Kaminski M, Niland J, Millenson M, Nademanee AP, Zelenetz A, LaCasce AS, Rodriguez MA. Radiation for diffuse large B-cell lymphoma in the rituximab era: analysis of the National Comprehensive Cancer Network lymphoma outcomes project. Cancer. 2015 Apr;121(7):1032-9.
Hamstra DA, Bae K, Hanks G, Hu C, Shipley WU, Pan CC, Roach M, Lawton CA, Sandler HM. Impact of Biochemical Failure Classification on Clinical Outcome: A Secondary Analysis of Radiation Therapy Oncology Group 9202 and 9413. Cancer. 2015 Mar;121(6):844-52.   PMCID: 4657945
Lee EQ, Kaley TJ, Duda DG, Schiff D, Lassman AB, Wong ET, Mikkelsen T, Purow BW, Muzikansky A, Ancukiewicz M, Huse JT, Ramkissoon S, Drappatz J, Norden AD, Beroukhim R, Weiss SE, Alexander BM, McCluskey CS, Gerard M, Smith KH, Jain RK, Batchelor TT, Ligon KL, Wen PY. A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients. Clin Cancer Res. 2015 Aug 15;21(16):3610-8.   PMCID: 4790106
Mehrazin R, Uzzo RG, Kutikov A, Ruth K, Tomaszewski JJ, Dulaimi E, Ginzburg S, Abbosh PH, Ito T, Corcoran AT, Chen DY, Smaldone MC, Al-Saleem T. Lymphopenia is an independent predictor of inferior outcome in papillary renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations. 2015 Sep;33(9):388e19-388e25.   PMCID: 4289664
Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman IM, Sharma P, CheckMate I. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. The New England journal of medicine. 2015 Nov 05;373(19):1803-13.
Murphy CT, Galloway TJ, Handorf EA, Wang L, Mehra R, Flieder DB, Ridge JA. Increasing time to treatment initiation for head and neck cancer: an analysis of the National Cancer Database. Cancer. 2015 Apr 15;121(8):1204-13.
Occhipinti S, Chambers SK, Lepore S, Aitken J, Dunn J. A Longitudinal Study of Post-Traumatic Growth and Psychological Distress in Colorectal Cancer Survivors. PLoS One. 2015 Jan;10(9):e0139119.   PMCID: 4587909
Persky DO, Miller TP, Unger JM, Spier CM, Puvvada S, Stea BD, Press OW, Constine LS, Barton KP, Friedberg JW, LeBlanc M, Fisher RI. Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313. Blood. 2015 Jan 08;125(2):236-41.   PMCID: PMC4287635
Plimack ER, Dunbrack RL, Brennan TA, Andrake MD, Zhou Y, Serebriiskii IG, Slifker M, Alpaugh K, Dulaimi E, Palma N, Hoffman-Censits J, Bilusic M, Wong YN, Kutikov A, Viterbo R, Greenberg RE, Chen DY, Lallas CD, Trabulsi EJ, Yelensky R, McConkey DJ, Miller VA, Golemis EA, Ross EA. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. Eur Urol. 2015 Dec;68(6):959-67.   PMCID: PMC4764095
Powers BD, Montes JA, Nguyen DC, Nick DA, Daly MP, Davey A, Willis AI. Demographic risk factors impacting timely radiation therapy completion after breast conserving surgery. Am J Surg. 2015 Nov;210(5):891-5.
Revenig LM, Canter DJ, Henderson MA, Ogan K, Kooby DA, Maithel SK, Liu Y, Kim S, Master VA. Preoperative quantification of perceptions of surgical frailty. J Surg Res. 2015 Feb;193(2):583-9.
Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. The New England journal of medicine. 2015 Aug 20;373(8):737-46.   PMCID: 4562797
Wang EH, Yu JB, Gross CP, Abouassaly R, Cherullo EE, Smaldone MC, Shah ND, Kiechle J, Trinh QD, Sun M, Kim SP. Association between Surgeon and Hospital Characteristics and Lymph Node Counts From Radical Prostatectomy and Pelvic Lymph Node Dissection. Urology. 2015 Apr;85(4):890-5.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term 80 and over Aged

80 and over Aged Aged Middle Aged Adult Female Male pathology therapeutic use drug therapy adverse effects mortality radiotherapy Young Adult Treatment Outcome Prognosis Disease-Free Survival methods Kaplan-Meier Estimate Antineoplastic Agents Local Neoplasm Recurrence therapy Chemoradiotherapy administration & dosage Follow-Up Studies Prospective Studies genetics blood Multivariate Analysis statistics & numerical data Lymph Nodes Retrospective Studies Quality of Life analogs & derivatives Prostatic Neoplasms Breast Neoplasms Lung Neoplasms Vincristine Radiosurgery Kidney Neoplasms Breast cancer Cyclophosphamide Neoplasm Invasiveness Monoclonal Antibodies Antineoplastic Combined Chemotherapy Protocols Head and Neck Neoplasms Mediastinal Neoplasms Non-Small-Cell Lung Carcinoma oligometastasis Biomarkers oligorecurrence Prostate-Specific Antigen Proportional Hazards Models Reproducibility of Results secondary Doxorubicin stereotactic radiation therapy Survival Rate Lymphatic Metastasis Squamous Cell Carcinoma Surveys and Questionnaires Combined Modality Therapy Prednisone mediastinal lymph node Age Factors neoplasm metastasis psychology Renal Cell Carcinoma metabolism Psychological Stress National Cancer Database cyclophosphamide Outcomes Kallikreins Rb1 One more Maximum Tolerated Dose Urothelial carcinoma Socioeconomic Factors Skin Neoplasms epidemiology Survival Analysis Frail Elderly Statistical Factor Analysis Toxicity Community Hospitals Ovarian cancer Genotype surgery head and neck cancer Veliparib Cisplatin Psychometrics Medicaid radiography Lymphocyte count High-Volume Hospitals DNA Repair Fallopian Tube Neoplasms Nonparametric Statistics Patient attitudes consolidation Magnetic Resonance Imaging Social Constraints Scale Pancreatic Neoplasms Dacarbazine Taxoids Prostatectomy Renal cell carcinoma Piperidines dosage Papillary renal cell carcinoma Karnofsky Performance Status Registries Hospitals Medicare Robotics doxorubicin Radiotherapy Dosage Translating Disparities intrusions Adenocarcinoma Radiotherapy Genetic Polymorphism Urinary Bladder Neoplasms Atm Combination Drug Therapy Peripheral Nerves Quinazolines Adolescent Survival Fancc Neoplasm Drug Resistance Fluorouracil United States Rituximab Retreatment Neutropenia immunology BRCA2 Genes Androgen Antagonists Postoperative Complications Monoclonal Antibodies-Murine-Derived BRCA1 Genes diagnosis chemically induced Treatment Failure BRCA2 Protein Surgery physiology
Last updated on Thursday, May 11, 2017